Pleural mesothelioma, a cancer mainly caused by asbestos, is a hard cancer to treat. Diagnosis usually occurs when it is in a late stage, leading to limited treatment options. New clinical trials are always being performed to try to find a new treatment approach that could possibly extend the lives[…]
New Study
CIRT Radiation Therapy Beneficial for Lung Cancer Patients
Surgery is usually the first choice for patients and doctors for the treatment of early-stage cancer. There are other options though like radiotherapy. A special type of radiotherapy called Carbon-ion radiotherapy (CIRT)has become popular with doctors. A study in Japan showing how the therapy can benefit patients with early-stage lung[…]
Checkmate743 Showed Higher Toxicity in a Real World Setting
A group of Australian patients receiving Checkmate743 therapy saw higher levels of toxicity compared to CheckMate743 clinical trial patients. Checkmate743 consists of a dual treatment of ipilimumab and nivolumab and is the standard of care for patients with unresectable pleural mesothelioma. Unresectable means patients are not able to receive surgery[…]
A New Biomarker Could Help Doctors Diagnose Mesothelioma
A new biomarker has been found for the diagnosis of mesothelioma by scientists in Japan. Information from this research could revolutionize how mesothelioma is diagnosed and treated in the future. Mesothelioma is a hard cancer to diagnose because it shares symptoms with other cancers. Cancers it can look like include[…]
Inhibiting YB-1 Can Help Improve Mesothelioma Treatments
Researchers in Vienna, Austria recently found a protein that could help treat mesothelioma patients. Researchers found the oncoprotein YB-1 which, when targeted, could make pleural mesothelioma more sensitive to chemotherapy and radiotherapy. The results of the study were published in the medical journal “Cancer Letters.” The study builds on earlier[…]
Chemoimmunotherapy Benefits Pleural Mesothelioma Patients
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving[…]
A Breath Test Could Soon be Available to Detect Mesothelioma
Researchers are trying to determine if a breath test can detect malignant pleural mesothelioma in patients exposed to asbestos. Early results are promising, but more research is needed to see what can be done for patients. The study, which is known as MESOBREATH 5, uses a test to detect volatile[…]
Extended Pleurectomy and Decortication Surgery Worse than Just Receiving Chemotherapy
Extended pleurectomy decortication surgery combined with chemotherapy is associated with worse outcomes compared to just chemotherapy alone. Researchers looked at extended pleurectomy and decortication surgery alongside chemotherapy and found that there are worse survival outcomes, a higher chance of serious adverse events, and a diminished quality of life compared to[…]
Orphan Drug Status Given to New Treatment for Mesothelioma
A new treatment for mesothelioma was recently given orphan drug status by the United States FDA. The company given orphan drug status is known as Avenge Bio, which is a biotechnology company working to create a new immunotherapy treatment regimen. It announced that it was given orphan drug status back[…]
Biomarkers Could be Used to Monitor Mesothelioma Patients
Researchers from Türkiye believe that biomarkers in the blood can help determine if patients are responding well to their treatment. Biomarkers are molecules that can let doctors know what is happening in the body. Even a small number of biomarkers could potentially help point doctors to progress being made in[…]
